Slide 1: First Quarter 2024 Results
May 8, 2024 15:00 (CEST) Formycon AG First Quarter 2024 Results
Slide 2: Disclaimer
Disclaimer This presentation may contain forward-looking statements and information which are based on our current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial si
Slide 3: Maximizing our assets along a clear path
Laser focus on pipeline execution and expansion Maximizing our assets along a clear path 2023 2024 Strong financial Important year Sustainable and operational to prepare the profitability with performance ground for the continuous pipeline next ignition growth stage 3 Formycon AG — Q1 2024
Slide 4: Highlights Q1/2024
Biosimilar Development HIGHLIGHTS Q1/2024 4 Formycon AG — Q1 2024
Slide 5: Launched & late-stage Projects well on track - Strong Newsflow ahead
Launched & late-stage Projects well on track - Strong Newsflow ahead Lucentis® Biosimilar Stelara® Biosimilar Candidate Eylea® Biosimilar Candidate [Ranibizumab] [Ustekinumab] [Aflibercept] ● Launch in Canada and Switzerland ● Settlement for Launch in Europe ● Regulatory procedures at FDA and by Tev
Slide 6: 2nd wave of Projects accelerating - Further Newsflow ahead
2nd wave of Projects accelerating - Further Newsflow ahead Keytruda® Biosimilar Candidate Undisclosed Biosimilar Candidates Undisclosed [Pembrolizumab] Biosimilar Candidates ● Intense preparation of clinical trials ● Cell line development with ● Selection process initiated along along the aligned cl
Slide 7: Financial Performance – Q1/2024
Financial Position FINANCIAL PERFORMANCE – Q1/2024 7 Formycon AG — Q1 2024
Slide 8: Profit & Loss fully on track Q1/2024 vs. Q1/2023
Profit & Loss fully on track Q1/2024 vs. Q1/2023 In € million Q1 2024 Q1 2023 Change in % Remarks − Q1/2023 includes 10m Upfront Fresenius, decreasing Revenue 17.7 32.4 -45% development services as anticipated Cost of sales -14.1 -16.9 -15% − Decreasing development services as anticipated − In 2023
Slide 9: Group asset structure as of Mar. 31, 2024 vs. Dec. 31, 2023
Group asset Structure as of Mar. 31, 2024 vs. Dec. 31, 2023 Balance Sheet total Equity Liabilities € 947.5 million € 580.8 million € 366.7 million + € 57.1 million + € 78.0 million - € 20.9 million +6% +16% -5% Equity Ratio Non-current assets vs. Cash & Cash Equivalents Total equity and liabilities
Slide 10: Cash-Flows and Working Capital
Cash-Flows and Working Capital Q1/2024 In € million 1Q 2024 Remarks Working Capital Mar. 31, 2024 • -5.5m EBITDA Net cash from operating -25.4 • -13m contract assets FYB202 Cash and cash equivalents 56.8 activities • -7m Inventory FYB206 Net cash from investing Current receivables 10.9 -6.1 • Develo
Slide 11: Outlook 2024 – Prepare the Ground
Financial Position O U T L O O K 2 0 2 4 – P R E PA R E T H E G R O U N D 11 Formycon AG — Q1 2024
Slide 12: 2024 outlook – Guidance confirmed
2024 outlook – Guidance confirmed Fiscal year 2024 Revenue EBITDA Adjusted EBITDA* Working Capital Guidance 2024: forecast − Revenue: on Track 55 to 65 -15 to -25 -5 to -15 10 to 20 − EBITDA: on Track − Adjusted EBITDA: on Track € million € million € million € million − Working Capital: on Track Key
Slide 13: Formycon on the Stock Market
Formycon on the Stock Market − Listed on Frankfurt Stock Exchange since June 2012 / Shareholder Structure SME segment “Scale” (Open Market) ● ~58 % Anchor Investors incl. Athos KG, − Registered capital: € 17,656,902 Active Ownership Capital, Wendeln & Cie. KG, Shares outstanding: 17,656,902 (w/o par
Slide 14: Continuous operational newsflow expected
Continuous operational newsflow expected Diversified portfolio of commercial, late and mid stage programs with multiple catalysts over the next 12 – 18 months Lucentis® 50% Further approvals Ophthalmology $2.0bn (Genentech Inc.) owned and launches 2022 [US*] [ex-US] [MENA] Stelara® Fully Approvals i
Slide 15: Biosimilar Opportunities
Biosimilar Opportunities 45 Blockbuster drugs with an expected global sales volume of more than 200 USD billion will lose their exclusivity in the coming years, creating huge opportunities for Biosimilars Year Number of blockbuster drugs losing exclusivity Cumulative global annual peak sales in USD
Slide 16: Preview AGM: Expanding highly experienced supervisory board
Preview AGM: Expanding highly experienced supervisory board Current Formycon Supervisory Board Team: Proposed resolutions to the AGM: • Election of two new members: Dr. Bodo Coldewey Nicholas Haggar • Election of a new member to the Dr. Olaf Stiller Peter Wendeln Wolfgang Essler Klaus Röhrig expande
Slide 17: Fully focused pure-play Biosimilar Company
Fully focused pure-play Biosimilar Company WE HAVE all ingredients to successfully WE ACT in a highly attractive market develop and commercialize a growing pipeline WE CREATED a strong Platform with WE ARE entering the next stage of the track record Formycon Growth Story 17 Formycon AG — Q1 2024
Slide 18: We are happy to answer your questions
Formycon AG WE ARE HAPPY TO ANSWER YO U R Q U E S T I O N S www.formycon.com 18 Formycon AG — Q1 2024